Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma

Gut

Volumn 57, Issue 3, 2008, Pages 344-351

  Serba, S ^a   Schmidt, J ^a   Wentzensen, N ^a   Ryschich, E ^a   Märten, Angela ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Surgery ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD8 ANTIGEN; GAMMA INTERFERON;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENCY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE TRANSFER; GENETIC TRANSFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PLASMID; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TUMOR GROWTH;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMALS; CD40 LIGAND; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GENE THERAPY; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; TRANSFECTION;

EID: 39649096284     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.130252     Document Type: Article

References (20)

1. Raraty MG, Magee CJ, Ghaneh P, et al. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol 2002;41:582-95.
2. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-27. Epub 15 September 2006.
3. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumour vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
4. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumours for use in clinical trials. Cancer J Sci Am 1998;4:194-203.
5. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003;185:476-80.
6. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35.
7. Costello RT, Gastaut JA, Olive D. What is the real role of CD40 in cancer immunotherapy? Immunol Today 1999;20:488-93.
8. Nakajima A, Kodama T, Morimoto S, et al. Antitumour effect of CD40 ligand: elicitation of local and systemic antitumour responses by IL-12 and B7. J Immunol 1998;161:1901-7.
9. Walker SR, Redlinger RE Jr, Barksdale EM Jr. Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J Pediatr Surg 2005;40:244-9; discussion 249-50.
10. French LE, Huard B, Wysocka M, et al. Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L. Blood 2005;105:219-25.
11. Shurin MR, Yurkovetsky ZR, Tourkova IL, et al. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumour-derived IL-10. Int J Cancer 2002;101:61-8.
12. Ryschich E, Märten A, Schmidt E, et al. Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. Eur J Cancer 2006;42:981-7. Epub 27 March 2006.
13. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984;44:717-26.
14. Ryschich E, Harms W, Loeffler T, et al. Radiation-induced leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma of the rat. Int J Cancer 2003;105:506-11.
15. Ridge J, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998;393:474-7.
16. Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001;19:3280-7.
17. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96:2917-24.
18. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998;114:1066-90.
19. Thienel U, Loike J, Yellin MJ. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol 1999;198:87-95.
20. Chiodoni C, Iezzi M, Guiducci C, et al. Triggering CD40 on endothelial cells contributes to tumour growth. J Exp Med 2006;203:2441-50.